Management of epithelial XXXX of low malignant potential.

@entity43 @entity1 @entity249 @entity146 @entity5 @entity189 @entity46 @entity34
The distinct pathologic and biologic nature of @entity43 of low malignant potential (LMP) has been officially recognized by FIGO and the World Health Organization. LMP @entity5 may comprise 10% of @entity43 ; they occur at a mean age of 40 years. Pregnancy, breast-feeding, and the use of oral contraceptives are protective against the development of @entity5 of LMP. A history of @entity249 and use of @entity249 drugs appear to increase the risk of these @entity5 . No association with @entity43 has been reported. The survival associated with these @entity5 is 99% at mean follow-up of 7 years for @entity1 with stage I disease, and 92% for those with @entity34 . Retrospectively, more @entity1 appear to have died from complications associated with adjuvant therapy than from progressive disease. The recommended treatment is surgical, consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node biopsies, peritoneal washings, and @entity5 debulking. In young @entity1 with early-stage disease, conservative surgery, preserving the uterus and contralateral ovary, is acceptable. A role has not yet been established for adjuvant therapy, whether radiotherapy or chemotherapy. Laboratory investigations have not demonstrated that these @entity5 represent an intermediate step between @entity43 and @entity189 nor have they identified that small subset of @entity5 with @entity146 clinical behavior. We should perhaps consider @entity5 of LMP in the same light as "benign" proliferative gynecologic conditions, such as @entity46 .
